What is the impact of aspirin on cardiovascular disease prevention in diabetes mellitus?
Aspirin has been found to have a positive effect on cardiovascular disease prevention in diabetes mellitus. Several studies have been conducted to assess the efficacy of aspirin for primary and secondary cardiovascular risk prevention in diabetes mellitus. These studies have found that aspirin is beneficial for reducing the risk of cardiovascular events and mortality in patients with diabetes mellitus. The Antithrombotic Trialists (ATT) Collaboration conducted a meta-analysis of individual participant data from randomized trials, which concluded that aspirin is effective for both primary and secondary prevention of vascular disease. Additionally, a systematic review of observational studies found that long-term low-dose aspirin is associated with a lower risk of bleeding compared to higher doses. Furthermore, the 2016 European Guidelines on cardiovascular disease prevention in clinical practice concluded that aspirin is beneficial for reducing the risk of cardiovascular events in patients with diabetes mellitus. Overall, the evidence suggests that aspirin is an effective intervention for cardiovascular disease prevention in diabetes mellitus.  